Related Experiment Video
Updated: Aug 9, 2026
06:03
Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis
Published on: July 12, 2011
Antiphospholipid antibodies and venous thromboembolism
J S Ginsberg1, P S Wells, P Brill-Edwards
1Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Blood
|November 15, 1995
Summary
Lupus anticoagulant (LA) strongly associates with venous thromboembolism (VTE), aiding diagnosis. Anticardiolipin antibodies (ACLA) lack clinical use in VTE patients. Neither LA nor APLA predicted warfarin resistance or recurrence in this study.
Area of Science:
- Hematology
- Immunology
- Vascular Medicine
Background:
- Antiphospholipid antibodies (APLA) clinical relevance in venous thromboembolism (VTE) without systemic lupus erythematosus is unclear.
- Limited data suggests APLA association with VTE and warfarin resistance.
Purpose of the Study:
- To evaluate the clinical relevance of APLA in patients with VTE.
- To assess the association of lupus anticoagulant (LA) and anticardiolipin antibodies (ACLA) with VTE.
- To determine if APLA influences warfarin therapy or VTE recurrence.
Main Methods:
- Prospective evaluation of unselected patients with suspected VTE.
- Objective testing for VTE and laboratory tests for LA and ACLA.
- Observation during and after anticoagulant therapy for recurrent VTE.
Main Results:
- Strong association found between LA and VTE (OR, 9.4).
- 14% of VTE patients had LA; ACLA showed no association with VTE.
- No recurrent VTE observed in patients with APLA on warfarin; no difference in recurrence post-discontinuation.
Conclusions:
- Testing for LA is clinically useful in VTE patients.
- ACLA measurement lacks clinical utility in VTE due to high false positive rates.
- APLA presence did not correlate with warfarin resistance or increased VTE recurrence risk in this cohort.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...